CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 47/68 (2017.08); A61K 47/6849 (2017.08); A61P 37/00 (2018.01); C07K 16/468 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); C07K 14/70578 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] | 18 Claims |
1. A pharmaceutical composition comprising:
a) an antibody, or antigen binding portion thereof that specifically binds to human CD40, and
b) a pharmaceutically acceptable carrier,
wherein the antibody or antigen binding portion thereof comprises a first polypeptide portion comprising a heavy chain variable region and a human heavy chain constant region, and a second polypeptide portion comprising a light chain variable region and a human light chain constant region, wherein:
said heavy chain variable region comprises a CDR1 comprising SEQ ID NO: 1, a CDR2 comprising SEQ ID NO: 2, and a CDR3 comprising SEQ ID NO: 3; and
said light chain variable region comprises a CDR1 comprising SEQ ID NO: 7, a CDR2 comprising SEQ ID NO: 8, and a CDR3 comprising SEQ ID NO: 9.
|